Page 300 - Read Online

Page 12 of 13 Harrod et al. Hepatoma Res 2019;5:28 I http://dx.doi.org/10.20517/2394-5079.2019.15

hepatocellular carcinoma. Hepatology 2017;66:661-3.
36. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, et al. Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran
patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.
37. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, et al. Hepatocellular carcinoma decreases the chance of
successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017;66:1173-81.
38. Radhakrishnan K, Adrian M. Di Bisceglie, K. Rajender Reddy, Joseph K. Lim, Josh Levitsky, et al. Impact of hepatocellular
carcinoma (HCC) and tumor treatment on sustained virologic response (SVR) rates with direct-acting antiviral (DAA) therapy for
hepatitis C: HCV-TARGET results. Hepatology 2017;66:755-6.
39. Soria A, Fabbiani M, Lapadula G, Gori A. Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with
hepatocellular carcinoma during treatment with direct-acting antivirals. Hepatology 2017;66:992-4.
40. Ji F, Yeo YH, Wei MT, Wei B, Dang S, et al. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment:
Do direct-acting antiviral regimens matter? Hepatology 2018;67:1180-2.
41. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
42. Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, et al. Direct-acting antivirals and hepatocellular carcinoma in chronic
hepatitis C: a few lights and many shadows. World J Gastroenterol 2018;24:2582-95.
43. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans
with hepatitis c virus infection. Hepatology 2016;64:130-7.
44. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV
therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
45. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular
carcinoma. J Hepatol 2018;68:25-32.
46. Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals:
Randomized Controlled Phase 3 Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last accessed on 27 June
2019]
47. Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV. Available from: https://clinicaltrials.gov/ct2/show/
NCT03551444 [Last accessed on 27 June 2019]
48. Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment (LONGHEAD). Available from: https://
clinicaltrials.gov/ct2/show/NCT03551444 [Last accessed on 27 June 2019]
49. Effect of DAAs on Behavior of HCC in HCV Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last
accessed on 27 June 2019]
50. Direct Acting Antiviral-Post Authorization Safety Study. Available from: https://clinicaltrials.gov/ct2/show/NCT03551444 [Last
accessed on 27 June 2019]
51. EASL. EASL recommendations on treatments of hepatitis C 2018. J Hepatol 2018;69:461-511.
52. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, et al. Clinical outcomes of patients undergoing antiviral therapy while
awaiting liver transplantation. J Hepatol 2017;67:1168-76.
53. Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, et al. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected
cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther 2018;47:1705-12.
54. Hassany M, Elsharkawy A, Maged A, Mehrez M, Asem N, et al. Hepatitis C virus treatment by direct-acting antivirals in successfully
treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol 2018;30:876-81.
55. Bas A, Samanci C, Gulsen F, Cantasdemir M, Kabasakal L, et al. Evaluation of liver stiffness after radioembolization by real-time
shearwave TM elastography : preliminary study. Cardiovasc Intervent Radiol 2014;38:957-63.
56. LLovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378-90.
57. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Dufour JF, et al. EASL - EORTC Clinical Practice Guidelines: Management of
hepatocellular carcinoma. J Hepatol 2012;56:908-43.
58. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
59. Himmelsbach K, Sauter D, Baumert TF, Ludwig L, Blum HE, et al. New aspects of an anti-tumour drug: Sorafenib efficiently inhibits
HCV replication. Gut 2009;58:1644-53.
60. Bürckstümmer T, Kriegs M, Lupberger J, Pauli EK, Schmittel S, et al. Raf-1 kinase associates with Hepatitis C virus NS5A and
regulates viral replication. FEBS Lett 2006;580:575-80.
61. Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, et al. HRas signal transduction promotes hepatitis c virus cell entry
by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013;13:302-13.
62. Menzel N, Fischl W, Hueging K, Bankwitz D, Frentzen A, et al. MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is
Essential for Production of Infectious Hepatitis C Virus Particles. PLoS Pathog 2012;8:1-17.
63. Descamps V, Helle F, Louandre C, Martin E, Brochot E, et al. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C
Virus infectious cycle in vitro. Antiviral Res 2015;118:93-102.
64. Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, et al. The antiviral effect of sorafenib in hepatitis c-related hepatocellular
carcinoma. Aliment Pharmacol Ther 2013;37:91-7.